🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

782 results for “S.A.” Clear

  1. Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen

    Pharma Mar S.A.

    Episodic and Chronic Migraine

    phase 3 small molecule active

    1 trial

  2. Furazidin, vaginal tablets, 5mg, Dalacin 20 mg/g hüvelykrém

    Pharma Mar S.A.

    Bacterial vaginosis

    phase 3 small molecule active

    1 trial

  3. GLUCOPHAGE 500 mg tabletki powlekane, Placebo

    Bial Portela & Companhia S.A.

    papillary thyroid carcinoma

    phase 3 small molecule active

    1 trial

  4. GLUCOTHERA PLUS

    Pharma Mar S.A.

    End-stage Kidney Disease

    phase 3 small molecule active

    1 trial

  5. GTX-102, GTX/UX Diluent and Flush Solution

    Pharma Mar S.A.

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  6. GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)

    Pharma Mar S.A.

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  7. Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets, Chlorambucil 2 mg tablets

    Pharma Mar S.A.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  8. HETLIOZ 20 mg hard capsules, Placebo will be provided in size and appearance identical to those containing tasimelteon and will be administered orally.

    Pharma Mar S.A.

    Delayed Sleep-Wake Phase Disorder (DSWPD)

    phase 3 small molecule active

    1 trial

  9. IMBRUVICA 140 mg hard capsules, Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules

    Pharma Mar S.A.

    High Risk Chronic Lymphocytic Leukaemia

    phase 3 small molecule active

    1 trial

  10. IMIPENEM, CILASTATIN AND RELEBACTAM, AMIKACIN , TIGECYCLINE , Nacubactam, AZACTAM 1 g, poudre et solution pour usage parentéral, COLISTIN , Cefepime Panpharma, 2 g, proszek do sporządzania roztworu do wstrzykiwań lub infuzji

    Pharma Mar S.A.

    Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)

    phase 3 small molecule active

    1 trial

  11. INZ-701

    Pharma Mar S.A.

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  12. INZ-701, INZ-701

    Pharma Mar S.A.

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  13. Ibutamoren Mesylate, Ibutamoren Mesylate, Matched placebo capsules administered orally once per day, Ibutamoren Mesylate

    Pharma Mar S.A.

    Growth Hormone Deficiency (GHD)

    phase 3 small molecule active

    1 trial

  14. Ilumetri 100 mg solution for injection in pre-filled syringe, Tildrakizumab placebo solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  15. Ilumetri 100 mg solution for injection in pre-filled syringe, tildrakizumab placebo solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  16. Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu

    Pharma Mar S.A.

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    phase 3 small molecule active

    1 trial

  17. Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Dexamethason 8 mg GALEN® Tabletten, Imnovid 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Dexamethasone 2mg Tablets, Imnovid 1 mg hard capsules, VELCADE 3.5 mg powder for solution for injection

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  18. Impetine® 20mg/g Gel, Bactroban 20 mg/g pomada

    Pharma Mar S.A.

    Impetigo

    phase 3 small molecule active

    1 trial

  19. JEMPERLI 500 mg concentrate for solution for infusion, Docetaxel Hikma 20 mg/1 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  20. JNJ 67896062, Matching Placebo for Macitentan 75 mg, JNJ 67896062, Matching Placebo for Macitentan 37.5 mg, Opsumit 10 mg film-coated tablets, Matching Placebo for Macitentan 10 mg

    Pharma Mar S.A.

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  21. JNJ-67896049, JNJ-67896049, Opsumit 10 mg film-coated tablets, JNJ-68150420, JNJ-67896049

    Pharma Mar S.A.

    pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  22. JNJ-67896062, JNJ-67896062

    Pharma Mar S.A.

    Pediatric pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  23. JR-141

    Pharma Mar S.A.

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  24. JR-141, Elaprase 2 mg/ml concentrate for solution for infusion

    Pharma Mar S.A.

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources